Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Contineum Therapeutics, Inc. - Common stock (NQ:CTNM)

11.05 +0.30 (+2.79%)
Streaming Delayed Price Updated: 12:48 PM EDT, Oct 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 37,094
Open 10.80
Bid (Size) 10.97 (1)
Ask (Size) 11.15 (2)
Prev. Close 10.75
Today's Range 10.80 - 11.57
52wk Range 3.350 - 20.24
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This Lululemon Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga
This Biogen Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga

Performance

YTD
-23.7%
-23.7%
1 Month
-1.1%
-1.1%
3 Month
+184.8%
+184.8%
6 Month
+80.3%
+80.3%
1 Year
-37.9%
-37.9%

More News

Read More
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
From Contineum Therapeutics, Inc.
Via Business Wire
Contineum Therapeutics to Present at September Investor Conferences
From Contineum Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Contineum (CTNM) Q2 R&D Jumps 78%
Via The Motley Fool
Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones
From Contineum Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
From Contineum Therapeutics, Inc.
Via Business Wire
Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference
From Contineum Therapeutics, Inc.
Via Business Wire
Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
From Contineum Therapeutics, Inc.
Via Business Wire
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development
From Contineum Therapeutics, Inc.
Via Business Wire
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors
From Contineum Therapeutics, Inc.
Via Business Wire
Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum
From Contineum Therapeutics, Inc.
Via Business Wire
Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones
From Contineum Therapeutics, Inc.
Via Business Wire
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791
From Contineum Therapeutics, Inc.
Via Business Wire
Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference
From Contineum Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
New Oriental Education, Walgreens And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
From Contineum Therapeutics, Inc.
Via Business Wire
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
From Contineum Therapeutics, Inc.
Via Business Wire
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Frequently Asked Questions

Is Contineum Therapeutics, Inc. - Common stock publicly traded?
Yes, Contineum Therapeutics, Inc. - Common stock is publicly traded.
What exchange does Contineum Therapeutics, Inc. - Common stock trade on?
Contineum Therapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Contineum Therapeutics, Inc. - Common stock?
The ticker symbol for Contineum Therapeutics, Inc. - Common stock is CTNM on the Nasdaq Stock Market
What is the current price of Contineum Therapeutics, Inc. - Common stock?
The current price of Contineum Therapeutics, Inc. - Common stock is 11.05
When was Contineum Therapeutics, Inc. - Common stock last traded?
The last trade of Contineum Therapeutics, Inc. - Common stock was at 10/03/25 12:48 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.